BioCryst Pharmaceuticals, Inc. (BCRX)
7.69
+0.06
(+0.79%)
USD |
NASDAQ |
Nov 06, 16:00
7.685
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Quarterly) : 57.97M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 57.97M |
| June 30, 2026 | 51.46M |
| March 31, 2026 | 59.26M |
| December 31, 2025 | 40.47M |
| September 30, 2025 | 44.27M |
| June 30, 2025 | 43.06M |
| March 31, 2025 | 36.94M |
| December 31, 2024 | 49.13M |
| September 30, 2024 | 40.77M |
| June 30, 2024 | 37.30M |
| March 31, 2024 | 46.19M |
| December 31, 2023 | 69.63M |
| September 30, 2023 | 46.46M |
| June 30, 2023 | 50.84M |
| March 31, 2023 | 47.98M |
| December 31, 2022 | 72.81M |
| September 30, 2022 | 52.35M |
| June 30, 2022 | 61.66M |
| March 31, 2022 | 65.04M |
| December 31, 2021 | 63.36M |
| September 30, 2021 | 49.74M |
| June 30, 2021 | 52.67M |
| March 31, 2021 | 42.26M |
| December 31, 2020 | 35.35M |
| September 30, 2020 | 30.24M |
| Date | Value |
|---|---|
| June 30, 2020 | 27.50M |
| March 31, 2020 | 29.87M |
| December 31, 2019 | 26.77M |
| September 30, 2019 | 25.12M |
| June 30, 2019 | 27.68M |
| March 31, 2019 | 27.49M |
| December 31, 2018 | 23.43M |
| September 30, 2018 | 22.01M |
| June 30, 2018 | 21.01M |
| March 31, 2018 | 18.44M |
| December 31, 2017 | 16.92M |
| September 30, 2017 | 17.51M |
| June 30, 2017 | 15.76M |
| March 31, 2017 | 16.77M |
| December 31, 2016 | 12.16M |
| September 30, 2016 | 14.10M |
| June 30, 2016 | 14.17M |
| March 31, 2016 | 20.58M |
| December 31, 2015 | 19.05M |
| September 30, 2015 | 20.07M |
| June 30, 2015 | 16.52M |
| March 31, 2015 | 17.12M |
| December 31, 2014 | 18.51M |
| September 30, 2014 | 13.04M |
| June 30, 2014 | 11.07M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen, Inc. | 2.111B |
| Halozyme Therapeutics, Inc. | 27.78M |
| Neurocrine Biosciences, Inc. | 351.80M |
| Agenus, Inc. | 11.65M |
| Anika Therapeutics, Inc. | 7.895M |